Enodia Therapeutics entered a research collaboration and licensing agreement with Pfizer to discover and develop small-molecule Sec61 inhibitors. Enodia will run discovery and optimization across multiple collaboration targets, while Pfizer will own later clinical, manufacturing, regulatory, and commercial execution. Enodia’s Sec61 platform is positioned around selective Sec61 translocon modulation intended to inhibit disease-driving proteins during synthesis. The company disclosed an upfront payment plus potential milestone payments, royalties, and a total deal value exceeding $500 million. The deal is notable for targeted protein regulation via translocation control—an area where large pharma is increasingly willing to partner for novel chemistry when early selectivity and safety hypotheses look credible.